Bulk ATAC-seq in glioblastoma spotlights GSTM1—a detox enzyme turned bad actor—whose wide-open promoter and high expression foretell poor survival. The work shows how promoter-centric epigenomics can uncover deadly tumour programs that conventional genomic screens miss.